EU Demands Pfizer Offload Its Infliximab Biosimilar In Hospira Buy
This article was originally published in The Pink Sheet Daily
Pfizer won EU antitrust approval for its plan to buy Hospira after promising to divest certain assets including its own biosimilar version of tumor necrosis factor inhibitor infliximab, to allay competition concerns. Still open are questions about possible buyers and what this means for competitors.
Register for our free email digests: